AMAG Pharmaceuticals — Merger or Acquisition (September 2014)
16 slides from AMAG Pharmaceuticals's merger presentation, Sep 29, 2014
Slide 1: Transformative Acquisition of Lumara Health Maternal Health Business
Transformative Acquisition of Lumara Health Maternal Health Business September 29, 2014
Slide 2: Forward-Looking Statements
Forward-Looking Statements ` This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited t
Slide 3: Forward-Looking Statements (cont.)
Forward-Looking Statements (cont.) 2 (13) in connection with the Lumara Health acquisition, we will incur a substantial amount of indebtedness and will have to comply with restrictive and affirmative debt covenants, including a requirement that we reduce our leverage over time, (14) the possibility
Slide 4: Lumara Health
ww Lumara Geamag © He bynes
Slide 5: Acquisition transforms AMAG into a profitable, high-growth multi-product specialty pharma
EXPERIENCED MANAGEMENT TEAM CORPORATE INFRASTRUCTURE Acquisition of Lumara Health transforms AMAG into a profitable, high-growth multi-product specialty pharmaceutical company, well positioned for continued expansion of the product portfolio 4 HEMATOLOGY/ONCOLOGY, HOSPITAL, NEPHROLOGY FERAHEME® MUGA
Slide 6: Transaction Highlights
Transaction Highlights Acquisition of Lumara Health and its maternal health division Annualized sales of >$180 million and EBITDA of $110 million* 72% revenue growth* Adds high-growth Makena product Only FDA-approved product to lower the risk of preterm singleton birth in certain at-risk women Rapid
Slide 7: Transaction Terms
6 Transaction Terms Performance-Based Financial Structure $675MM consideration (~3.75 times annualized sales) Up to $350MM of additional consideration based on Makena sales, including milestones of $300MM, $400MM and $500MM* Operational Structure Lumara Health will operate as separate business unit
Slide 8: Lumara Maternal Health Business
Lumara Maternal Health Business 7 Privately-held specialty pharmaceutical company focused on maternal health Flagship product, Makena Commercial team with deep experience with OB/GYN sub-specialty Lumara Health’s new commercial leadership is pursuing patient-centric business strategy Makena® is a pr
Slide 9: Makena: A Valuable Asset
Makena: A Valuable Asset 8 Significant Makena Unit and Dollar Growth Demonstrated EBITDA Growth Significant top-line revenue and growth Strong sequential quarter growth last 2+ years >$180MM annualized Makena sales based on most recent trailing 3-month actuals* 72% revenue growth last twelve months
Slide 10: Lumara Health: Natural Fit for AMAG
Lumara Health: Natural Fit for AMAG Women’s health segment includes one of the largest pools of iron deficiency anemia (IDA) patients, not yet treated with IV iron Establishes immediate presence within women’s health sub-specialty for future Feraheme growth* AMAG working with FDA to finalize path fo
Slide 11: Makena: Standard-of-Care Therapy
Makena: Standard-of-Care Therapy Strong Makena Efficacy Data(4,5) Rate of Birth 32% Improvement Control N=153(%) Makena N=310(%) Before 35 weeks Before 32 weeks Before 37 weeks 31% Improvement 39% Improvement Length of pregnancy is one of the most important factors in a newborn’s overall health and
Slide 12: Makena: $1B Market Opportunity
Orphan patient population: ~140k-160k estimated patients per year Potential to increase market share +30% revenue opportunity with enhanced patient compliance (injections per patient) Favorable market dynamics and reimbursement trends Market Share Based on Patients(2) Makena: $1B Market Opportunity(
Slide 13: Favorable Market Dynamics
Favorable Market Dynamics Federal Drug Quality and Security Act (enacted 11/2013) Clarifies roles of traditional compounding and FDA-approved medicines Makes clear FDA's authority over drug compounding and requires agency to engage and coordinate with states 12 12 “If FDA identifies a registered out
Slide 14: Success Factors for Achieving Makena Growth Potential
Success Factors for Achieving Makena Growth Potential 13 Operational Excellence Increase physician and patient awareness Expand commercial/Medicaid access and reimbursement Partner with high potential distribution channels including compounding pharmacies Improve patient compliance (more injections
Slide 15: Financially Transformative Transaction
Financially Transformative Transaction Preliminary 2015 View of Combined Company 14 + Income Statement 2015 Pro Forma (in millions) U.S. product sales ~$350 Operating synergies $20 Balance Sheet At Closing (in millions) Cash and investments $100 Senior debt $340 Convertible debt $200 Basic shares ou
Slide 16: Transaction Creates Significant Shareholder Value
Transaction Creates Significant Shareholder Value Transforms AMAG into a profitable, high-growth, multi-product specialty pharmaceutical company Adds a proven product in a therapeutic area of strategic interest for Feraheme Provides a new commercial platform for portfolio expansion through business
AMAG Pharmaceuticals — Merger or Acquisition (September 2014) on 6ix